$32.96
-0.58 (-1.73%)
HIMS News30 articles
Hims & Hers Health Surges on Weight-Loss Drug Strategy Optimism
Hims & Hers Health (HIMS) shares rallied 6.6% to $28.98 on heavy volume, bucking a tech selloff, as investors refocus on the company's weight-loss drug scaling potential after a challenging quarter.
Hims Completes $1.15B Eucalyptus Acquisition, Shares Dip Slightly
Hims & Hers shares fell 0.9% after completing the $1.15 billion Eucalyptus acquisition, gaining 850,000 customers and international reach, but facing execution risks and U.S. weight-loss drug plan shifts.
Hims & Hers Shares Slide on Convertible Note Sale, Dilution Worries
Hims & Hers Health shares declined 4% in pre-market trading after announcing a $300 million convertible note sale to finance its Eucalyptus acquisition and technology investments.
Market Update: Bapcor Shares Fall on Lowered EBITDA Forecast
Bapcor shares fell 18% after lowering FY2026 EBITDA forecast to $144-150 million amid cost pressures. Nvidia earnings loom, Indian shares decline on oil surge, and Hubbbell, Welltower show strength.
Stocks Dip as Oil Surge Fuels Inflation Fears, Fed Cut Hopes Fade
US stocks retreated Tuesday as a hotter-than-expected April CPI report and surging oil prices dampened rate-cut expectations, with tech and chip stocks leading declines.
Hims & Hers Shares Drop as GLP-1 Strategy Shift Squeezes Margins
Hims & Hers Health shares tumbled 14.6% to $24.89 after a Q1 net loss of $92.1 million, as the company pivots from compounded GLP-1s to branded drugs, pressuring margins.
CPI Surge and Oil Spike End Wall Street's Record Rally
U.S. stocks retreated Tuesday after a hotter-than-expected April CPI report and a surge in oil prices to $107.72 halted Wall Street's record run. Markets now price zero Fed rate cuts in 2026.
Nasdaq Futures Dip as Oil Surge and CPI Data Test Wall Street Records
Nasdaq 100 futures fell 0.68% early Tuesday as traders braced for April CPI data and oil prices surged, threatening Wall Street's recent record highs. Goldman Sachs pushed its rate cut forecast to December.
S&P 500 and Nasdaq Close at Records; CPI Data in Focus
S&P 500 and Nasdaq close at records as AI-chip stocks rally. After-hours: BuzzFeed jumps on Byron Allen deal, GoPro rises on strategic review, Hims & Hers falls on unexpected loss.
Hims & Hers Stock Plunges on Q1 Loss, Weight-Loss Strategy Shift
Hims & Hers shares dropped 10% on a surprise Q1 net loss and revenue miss. The company raised its 2026 sales forecast but cut profit outlook amid a costly shift to branded weight-loss drugs.
Hims & Hers Earnings: Weight-Loss Strategy in Focus as GLP-1 Shift Unfolds
Hims & Hers Health reports Q1 earnings Monday after close, with Wall Street expecting ~$617M revenue. The key focus: how its weight-loss business performs after shifting from compounded GLP-1 drugs to FDA-approved options from Novo Nordisk.
Hims & Hers Health Faces GLP-1 Pivot Ahead of Q1 Earnings
Hims & Hers Health shares surged 10.2% ahead of Q1 earnings, as investors watch the company's pivot from compounded to branded GLP-1 drugs amid FDA regulatory changes.
Hims & Hers Health Gears for Earnings Amid Weight-Loss Drug Shifts
Hims & Hers Health shares surged 9.3% to $28.03 ahead of its May 11 earnings report, with options pricing a 14.8% move. The company is navigating FDA rules on compounded weight-loss drugs.
Hims & Hers Surges on JPMorgan Upgrade and GLP-1 Expansion
Hims & Hers stock jumped 9% after JPMorgan gave an overweight rating and $35 target. The company now offers Eli Lilly's Zepbound and Foundayo through LillyDirect.
Hims Expands Branded GLP-1 Access with Lilly's Zepbound and Foundayo
Hims & Hers Health now offers Eli Lilly's Zepbound and Foundayo via LillyDirect, broadening its branded GLP-1 lineup amid a competitive cash-pay market.
Amazon's GLP-1 Launch Pressures Hims & Hers, Telehealth Rivals
Shares of Hims & Hers Health dropped Tuesday after Amazon launched a GLP-1 weight-management program, heightening competition in the telehealth sector. The company is pivoting from compounded drugs to FDA-approved branded medications.
Hims & Hers Soars on FDA Catalyst as Omnicell Underperforms
Hims & Hers Health shares surged nearly 9% Monday, extending a strong weekly gain ahead of its May earnings report and a key FDA meeting on peptides. Omnicell reported mixed Q4 results with a net loss.
FDA Peptide Review Sparks Rally for Hims & Hers Health
Shares of Hims & Hers Health climbed sharply after regulators signaled a review of peptide restrictions, a development analysts view as a positive shift for the company's growth strategy.
Hims & Hers Stock Jumps on FDA's Peptide Policy Review
Shares of Hims & Hers Health climbed sharply after the U.S. Food and Drug Administration said it will reconsider regulations on certain peptides. The company, which acquired a peptide facility last year, sees this as an opportunity to expand beyond the GLP-1 market.
Hims & Hers Stock Stabilizes as Novo Deal Shifts Focus to Profitability
Hims & Hers Health shares traded near $23.82 Friday, stabilizing after a week of volatility driven by its new branded obesity drug agreement with Novo Nordisk. The shift from compounded medications raises margin concerns despite reducing regulatory risk.
Hims & Hers Stock Extends Rally on Novo Nordisk Patent Settlement
Shares of Hims & Hers Health continued their ascent following a resolution to a patent conflict with Novo Nordisk, which will reintroduce branded GLP-1 medications to its service. Analysts have upgraded the stock but caution about potential margin pressures.
Hims & Hers Soars on Novo Nordisk Partnership, Analyst Targets Rise
Shares of Hims & Hers Health skyrocketed approximately 49% over two sessions following a new distribution agreement with Novo Nordisk. The deal resolves a legal dispute and will bring branded GLP-1 drugs to the telehealth platform, leading several analysts to raise their price targets.
Markets Brace for Inflation Data as Oil Surge Dents Rate Cut Hopes
U.S. equity futures declined sharply Monday amid surging oil prices and weak jobs data, pushing back expectations for Federal Reserve rate cuts. Investors await critical inflation reports due this week.
Hims & Hers Shares Jump on Novo Nordisk Partnership Revival
Hims & Hers Health shares surged in premarket trading Monday following reports that Novo Nordisk will resume selling its weight-loss drugs through the telehealth platform. The move marks a reversal from a patent dispute last month.
Hims & Hers Faces SEC Probe, Novo Nordisk Lawsuit as Analysts Cut Targets
Hims & Hers Health shares held steady premarket following disclosures of an SEC probe and a patent lawsuit from Novo Nordisk. Analysts at BTIG and Citi downgraded the stock, citing regulatory risks.
Hims & Hers Shares Stabilize After Novo Nordisk Patent Lawsuit Rattles Weight-Loss Strategy
Hims & Hers stock edged up 0.1% premarket following steep declines after Novo Nordisk filed a patent lawsuit over compounded semaglutide. Investors await court developments, FDA signals, and the company's Feb. 23 earnings.
Hims & Hers Stock Extends Slide Amid Weight-Loss Pill Halt, Regulatory Pressure
Hims & Hers Health shares fell another 4.2% premarket Tuesday, compounding a 16% drop Monday, after discontinuing its compounded semaglutide pill. The company faces a patent lawsuit from Novo Nordisk and potential FDA action.
Hims & Hers Shares Plunge 16% After Halting $49 Weight-Loss Pill Amid Novo Nordisk Lawsuit
Hims & Hers Health stock tumbled in after-hours trading following the withdrawal of its compounded semaglutide product and a patent infringement lawsuit from Novo Nordisk. Leerink Partners reduced its price target on the company.
Dow Futures Edge Higher Amid Mixed Premarket Action, Focus on Jobs and CPI Data
U.S. stock futures were mixed early Monday, with Dow futures gaining while S&P 500 and Nasdaq 100 futures dipped. Investors await key January employment and inflation reports later this week.
Novo Nordisk Shares Surge as Hims Abandons Low-Cost Semaglutide Pill
Novo Nordisk stock climbed over 8% after Hims & Hers canceled plans for a $49 compounded weight-loss pill. The move follows FDA warnings against unapproved GLP-1 drug marketing.